Trials / Unknown
UnknownNCT03757390
Bioequivalence Study of CJ-30060 in Healthy Volunteers
An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CJ-30060 in Healthy Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- HK inno.N Corporation · Industry
- Sex
- All
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
Detailed description
The purpose of this study is to compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exforge® tab 5/160mg, Crestor® tab 10mg | co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg |
| DRUG | CJ-30060 5/160/10mg | Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg |
Timeline
- Start date
- 2018-11-09
- Primary completion
- 2018-12-14
- Completion
- 2018-12-14
- First posted
- 2018-11-28
- Last updated
- 2018-11-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03757390. Inclusion in this directory is not an endorsement.